Track topics on Twitter Track topics that are important to you
Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive...
NewsPfizer creates an alliance with Allogene Therapeutics to expedite the development of allogeneic CAR T cell therapy.
Allogene Therapeutics Inc raised $288 million by offering 18.4 million shares, putting a spotlight on the biotech IPO boom this year
Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public off...
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Allogene Therapeutics Inc. said that they have entered into an asset contribution agreement for Pfizer's portfolio of assets related to allogeneic c...
NEW YORK & SOUTH SAN FRANCISCO–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) and Allogene Therapeutics, Inc. (Allogene) today announced that the two companies have entered into an asset contr...
Immuno-oncology firm Allogene Therapeutics Inc. filed for its initial public offering and plans to trade on the Nasdaq.
Allogene Therapeutics raised $120 million through private financing, which it intends to use in developing allogeneic chimeri -More-
ALDEX GS™ Tablets
ALDEX GS DMTablets
To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.
Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor...
Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...
Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...
Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...
Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeuticsâ¢ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...
We have published hundreds of Allogene Therapeutics, Inc. news stories on BioPortfolio along with dozens of Allogene Therapeutics, Inc. Clinical Trials and PubMed Articles about Allogene Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Allogene Therapeutics, Inc. Companies in our database. You can also find out about relevant Allogene Therapeutics, Inc. Drugs and Medications on this site too.